

Cipaglucoasidase alfa-atga (Pombiliti™) + Miglustat (Opfolda™)

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

| | | |
|---|--|---|
| AL – Age Limit | DS – Maximum Days’ Supply Allowed | PU – Prior Use of Other Medication is Required |
| BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age | DT – Duration of Therapy Limit | QL – Quantity Limit |
| BY – Diagnosis Codes Bypass Some Requirements | DX – Diagnosis Code Requirement | RX – Specific Prescription Requirement |
| CL – Additional Clinical Information is Required | ER – Early Refill | TD – Therapeutic Duplication |
| CU – Concurrent Use with Other Medication is Restricted | MD – Maximum Dose Limit | YQ – Yearly Quantity Limit |
| DD – Drug-Drug Interaction | MME – Maximum Morphine Milligram Equivalent is Restricted | |

Cipaglucosidase alfa-atga (Pombiliti™) + Miglustat (Opfolda™)

POS Edits

DX – Pharmacy claims for this agent must be submitted with an appropriate diagnosis code found at [THIS LINK](#).

| Revision / Date | Implementation Date |
|--------------------------------------|---------------------|
| Created POS Document / November 2023 | April 2024 |